IP Library Granted Patent US 10,556,112
Granted Patent B1
US 10,556,112 · App. 16/048,148 · Granted Feb 11, 2020

Spinal cord modulation for inhibiting pain via short pulse width waveforms, and associated systems and methods

Inventor: Sangsoo Wesley Park (San Jose, CA)
Assignee: Nevro Corp.
A61N1/36175A61N1/0553A61N1/36071A61N1/36157A61N1/36171
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,556,112
App. No.
16/048,148
Granted
Feb 11, 2020
Kind
B1
Abstract

Short pulse width spinal cord modulation for inhibiting pain with reduced side effects and associated systems and methods are disclosed. In particular embodiments, modulation signal has pulse widths in the range of from about 10 microseconds to about 50 microseconds may be applied to the patient's spinal cord region to address chronic pain without using paresthesia or tingling to mask or cover the patient's sensation of pain. In other embodiments, modulation in accordance with similar parameters can be applied to other spinal or peripheral locations to address other indications.

Claims (14)

1. A spinal cord stimulation system for reducing or eliminating pain in a patient, the system comprising:

an implantable signal generator that, in operation, generates a non-paresthesia-producing therapy signal, wherein at least a portion of the therapy signal is at a frequency of from 500 Hz to 1,200 Hz, with a pulse width in a pulse width range from 10 microseconds to 50 microseconds, and a current amplitude in a current amplitude range from 0.5 mA to 7 mA; and

a signal delivery device electrically coupled to the implantable signal generator to deliver the therapy signal to the dorsal column of the patient's spinal cord.

2. The system of claim 1 , wherein the implantable signal generator generates the therapy signal at a duty cycle.

3. The system of claim 2 , wherein the duty cycle is 100%.

4. The system of claim 2 , wherein the duty cycle is 50-100%.

5. The system of claim 2 , wherein the frequency is applied throughout the length of an on period in the duty cycle.

6. The system of claim 2 , wherein the frequency is applied during a portion of an on period in the duty cycle.

7. The system of claim 1 , wherein the therapy signal is delivered at a current amplitude of 2.5 mA.

8. The system of claim 1 , wherein at least a portion of the therapy signal is a square-wave signal.

9. The system of claim 1 , wherein the signal delivery device is a percutaneous lead.

10. The system of claim 1 , wherein the signal delivery device is a paddle lead.

11. The system of claim 1 , wherein the signal delivery device is an elongated lead having one or more electrodes.

12. The system of claim 1 , wherein the signal delivery device is an elongated lead having a bipole arrangement of electrodes.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Apr 4, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: NEVRO CORP.
Reel/Frame 070743/0001 →
PATENT SECURITY AGREEMENT Recorded Dec 1, 2023
From: NEVRO CORP.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 065744/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2018
From: PARK, SANGSOO WESLEY
To: NEVRO CORP.
Reel/Frame 046981/0781 →
Continuity (2)
Continuation 14534769 · Nov 6, 2014
Provisional Application 61901255 · Nov 7, 2013
Cited By (2)
US 12,390,645 US 12,465,776